✦ LIBER ✦

Safety and efficacy of vildagliptin versus placebo in patients with type 2 diabetes and moderate or severe renal impairment: a prospective 24-week randomized placebo-controlled trial

✍ Scribed by V. Lukashevich; A. Schweizer; Q. Shao; P.-H. Groop; W. Kothny

Book ID: 109046203
Publisher: John Wiley and Sons
Year: 2011
Tongue: English
Weight: 569 KB
Volume: 13
Category: Article
ISSN: 1462-8902
DOI: 10.1111/j.1463-1326.2011.01467.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Efficacy and safety of vildagliptin and

Efficacy and safety of vildagliptin and voglibose in Japanese patients with type 2 diabetes: a 12-week, randomized, double-blind, active-controlled study

✍ Y. Iwamoto; A. Kashiwagi; N. Yamada; S. Terao; N. Mimori; M. Suzuki; H. Tachiban 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 634 KB

Effect of dapagliflozin in patients with

Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24-week, double-blind, placebo-controlled trial

✍ K. Strojek; K. H. Yoon; V. Hruba; M. Elze; A. M. Langkilde; S. Parikh 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 662 KB

Efficacy and safety of initial combinati

Efficacy and safety of initial combination therapy with linagliptin and pioglitazone in patients with inadequately controlled type 2 diabetes: a randomized, double-blind, placebo-controlled study

✍ R. Gomis; R.-M. Espadero; R. Jones; H. J. Woerle; K. A. Dugi 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 849 KB

Efficacy and safety of topical WBI-1001

Efficacy and safety of topical WBI-1001 in patients with mild to severe atopic dermatitis: results from a 12-week, multicentre, randomized, placebo-controlled double-blind trial

✍ R. Bissonnette; Y. Poulin; Y. Zhou; J. Tan; H.C. Hong; J. Webster; W. Ip; L. Tan 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 336 KB

Efficacy and safety of four doses of lum

Efficacy and safety of four doses of lumiracoxib versus diclofenac in patients with knee or hip primary osteoarthritis: A phase II, four-week, multicenter, randomized, double-blind, placebo-controlled trial

✍ Schnitzer, Thomas J. ;Beier, Jannie ;Geusens, Piet ;Hasler, Paul ;Patel, Sanjay 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 128 KB 👁 3 views

## Abstract ## Objective To compare the efficacy and tolerability of the novel cyclooxygenase 2‐selective inhibitor lumiracoxib with placebo and diclofenac in osteoarthritis (OA). ## Methods Adults (n = 583) with knee or hip OA were randomized to receive for 4 weeks lumiracoxib 50, 100, or 200 m

A multicenter, randomized, placebo-contr

A multicenter, randomized, placebo-controlled, double-blind phase II trial evaluating the optimal dose, efficacy and safety of LC 15-0444 in patients with type 2 diabetes

✍ E. J. Rhee; W. Y. Lee; K. H. Yoon; S. J. Yoo; I. K. Lee; S. H. Baik; Y. K. Kim; 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 531 KB